116 related articles for article (PubMed ID: 17478562)
1. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer.
Sieuwerts AM; Usher PA; Meijer-van Gelder ME; Timmermans M; Martens JW; Brünner N; Klijn JG; Offenberg H; Foekens JA
Clin Chem; 2007 Jul; 53(7):1280-8. PubMed ID: 17478562
[TBL] [Abstract][Full Text] [Related]
2. Expression of MMP and TIMP mRNA in peripheral blood leukocytes of patients with invasive ductal carcinoma of the breast.
Wieczorek E; Galicki M; Tomasik B; Krol M; Jablonska E; Fendler W; Gromadzinska J; Morawiec Z; Wasowicz W; Reszka E
Int J Biol Markers; 2016 Jul; 31(3):e309-16. PubMed ID: 27032379
[TBL] [Abstract][Full Text] [Related]
3. A TIMP-1 splice variant transcript: possible role in regulation of TIMP-1 expression.
Obro NF; Lademann U; Birkenkamp-Demtroder K; Holten-Andersen L; Brünner N; Offenberg H
Cancer Lett; 2008 Apr; 262(1):64-70. PubMed ID: 18180096
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TIMP-1 in non-small cell lung cancer.
Pesta M; Kulda V; Kucera R; Pesek M; Vrzalova J; Liska V; Pecen L; Treska V; Safranek J; Prazakova M; Vycital O; Bruha J; Holubec L; Topolcan O
Anticancer Res; 2011 Nov; 31(11):4031-8. PubMed ID: 22110238
[TBL] [Abstract][Full Text] [Related]
5. Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue.
Usher PA; Sieuwerts AM; Bartels A; Lademann U; Nielsen HJ; Holten-Andersen L; Foekens JA; Brünner N; Offenberg H
Mol Oncol; 2007 Sep; 1(2):205-15. PubMed ID: 19383295
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer.
Wang YY; Li L; Zhao ZS; Wang HJ
World J Surg Oncol; 2013 Apr; 11():81. PubMed ID: 23548070
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Luther T; Kotzsch M; Meye A; Langerholc T; Füssel S; Olbricht N; Albrecht S; Ockert D; Muehlenweg B; Friedrich K; Grosser M; Schmitt M; Baretton G; Magdolen V
Thromb Haemost; 2003 Apr; 89(4):705-17. PubMed ID: 12669126
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients.
Rot S; Kaune T; Taubert H; Greither T; Kotrba J; Güttler A; Wichmann H; Bilkenroth U; Wienke A; Al-Nawas B; Bache M; Vordermark D; Wickenhauser C; Bethmann D; Eckert AW; Kappler M
BMC Cancer; 2019 Feb; 19(1):155. PubMed ID: 30770730
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
11. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
Kotzsch M; Farthmann J; Meye A; Fuessel S; Baretton G; Tjan-Heijnen VC; Schmitt M; Luther T; Sweep FC; Magdolen V; Span PN
Eur J Cancer; 2005 Nov; 41(17):2760-8. PubMed ID: 16256342
[TBL] [Abstract][Full Text] [Related]
13. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
14. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
15. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.
Würtz SØ; Christensen IJ; Schrohl AS; Mouridsen H; Lademann U; Jensen V; Brünner N
Mol Cell Proteomics; 2005 Apr; 4(4):483-91. PubMed ID: 15640527
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
[TBL] [Abstract][Full Text] [Related]
18. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer.
Inagaki D; Oshima T; Yoshihara K; Tamura S; Kanazawa A; Yamada T; Yamamoto N; Sato T; Shiozawa M; Morinaga S; Akaike M; Fujii S; Numata K; Kunisaki C; Rino Y; Tanaka K; Masuda M; Imada T
Anticancer Res; 2010 Oct; 30(10):4127-30. PubMed ID: 21036730
[TBL] [Abstract][Full Text] [Related]
20. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
Span PN; Tjan-Heijnen VC; Heuvel JJ; de Kok JB; Foekens JA; Sweep FC
Clin Chem; 2006 Sep; 52(9):1693-700. PubMed ID: 16873289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
